Published in Gene Therapy Weekly, August 4th, 1997
While exogenous IL-16 inhibits HIV replication by 70 to 90 percent, constitutive expression of 1,000-fold smaller amounts of the cytokine by genetically engineered CD4+ cells inhibited viral replication by as much as 99 percent.
"In the long term, gene therapy might be used to introduce IL-16 cDNA (perhaps with other anti-HIV genes) into CD4+ stem cells from HIV infected patients, before these stem cells give rise to CD4+ HIV susceptible cells, and render them resistant to HIV infection," suggested Paul Zhou and colleagues of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.